Categories
Cardiovascular
Diagnostics
Endocrinology
Health Insurance
Medical Devices
Mental Health
Nutrition
Oncology
Public Health
Sexual Health
buy vibrator.
Popular Articles

Invatec Officially Launches Coronary Drug-Eluting Balloon Platform IN.PACT™ Falcon At EuroPCR
Invatec, a comprehensive innovator of interventional products, today announced the availability of its newly CE marked coronary balloon, the IN.PACT™ Falcon paclitaxel-eluting PTCA balloon catheter at the EuroPCR Congress 2009 in Barcelona, Spain. This is one of the first drug-eluting balloons designed specifically to treat atherosclerosis in the coronary arteries and underscores Invatec"s commitment to robust scientific research into the reduction of re-intervention rates in the treatment of Coronary Artery Disease (CAD).
pharmacy online
American Red Cross Bleeds Frontline Blood Drive Workers
Teamsters General President Hoffa called on the American Red Cross to support its frontline blood drive workers whose efforts help safeguard America"s blood supply. The Red Cross is currently pursuing a campaign against its frontline workers that would worsen working conditions, push down living standards, undermine workers" rights to representation, threaten safety standards and create a disposable work force.
News of the day
Like Burrs On Your Clothes, Molecule-Size Capsules Can Deliver Drugs By Sticking To Targeted Cells
It is now possible to engineer tiny containers the size of a virus to deliver drugs and other materials with almost 100 percent efficiency to targeted cells in the bloodstream.
Medical Devices

Data Demonstrates Long-Term Reduction In Seizure Frequency With Novel Once Daily Anti-Epileptic Zebinix(R)

Data presented yesterday, in Budapest, demonstrated that add-on treatment with the novel, once-daily anti-epileptic Zebinix®* (eslicarbazepine acetate; ESL) resulted in a marked and sustained decrease in seizure frequency over the long-term. Results from the one-year extension of a pivotal Eslicarbazepine Acetate phase III study were presented at the International Congress for Epilepsy in Budapest, Hungary. Patients not controlled with existing anti-epileptic drugs who were given eslicarbazepine acetate as an add-on treatment experienced a mean reduction in seizure frequency of more than 61% (95%CI: -68.2%, -55.5%). Nearly 65% of patients were classified as responders, meaning that they had achieved at least a 50% reduction in seizure frequency with Zebinix® treatment1. "These data continue to demonstrate the efficacy and safety of Zebinix® in the treatment of partial onset seizures", said Joyce Cramer, research scientist at Yale University School of Medicine, USA and President of The Epilepsy Therapy Project. "Epilepsy is a devastating condition that can be very difficult to manage and the availability of eslicarbazepine acetate adds an important new choice of therapy for patients who are in vital need of better seizure control." Epilepsy is one of the most common neurological diseases, affecting approximately one in 100 people. Treatment of partial-onset seizures, the most common type of epilepsy, remains a constant challenge and up to 40% of patients with partial seizures do not achieve seizure control with current anti-epileptics. Additional studies presented at the IEC further reinforce the efficacy and safety of eslicarbazepine acetate in the treatment of partial-onset seizures, with or without secondary generalisation. Pooled data from more than 1,000 patients enrolled in the three pivotal phase III studies demonstrated that add-on therapy with once-daily Zebinix® (800mg and 1200mg) was effective in reducing partial-onset seizures in patients not controlled with one of the most commonly used anti-epileptics, carbamazepine (CBZ), (pBIAL


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):

© Copyright 2009